Onartuzumab for Gastroesophageal Adenocarcinoma

Publication
Article
Special ReportsGastrointestinal Cancers (Issue 4)
Volume 4
Issue 1

Manish A Shah, MD, talks about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma.

Manish A Shah, MD, director of gastrointestinal oncology at Weill Cornell Medical College/New York Presbyterian Hospital, talks about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma (GEC).

Clinical Pearls:

  • The MET pathway is often overexpressed in gastric cancer. If there is a MET amplification in addition to the overexpression, the cancer can be more aggressive.
  • The study found that the addition of onartuzumab to FOLFOX did not improve progression-free survival or overall survival in either an unselected population or in MET-positive patients.
  • More research is needed to identify patients that benefit from MET inhibition
Related Videos
David Zhen, MD, an expert on gastric cancer
David Zhen, MD, an expert on gastric cancer
David Zhen, MD, an expert on gastric cancer
David Zhen, MD, an expert on gastric cancer
David Zhen, MD, an expert on gastric cancer
Related Content